Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum...
M. Camilli, M. Ortenzi, L. Leo et al.· Journal of Cardiovascular Ph...· 0 citations
Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD19 has demonstrated efficacy as salvage treatment for patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL), however, a direct comparison between CAR T activity and other salvage treatments has not previously been performed. This s...
A. Guidetti, I. Dogliotti, A. Chiappella et al.· Haematologica· 0 citations
The prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma receiving commercial CAR‐T cells is evaluated, focusing on treatment‐related toxicities.
Eugenio Galli, D. Mannina, Alessandro Corrente et al.· European Journal of Haematol...· 1 citation
The HFA-ICOS score effectively stratifies mortality and cardiotoxicity risk among R-COMP–treated patients and supports its application in routine treatment of lymphomas requiring anthracycline-based therapy.
M. Camilli, I. Torre, L. Leo et al.· European Heart Journal, Supp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.